← board
CYPH
distress 7/10 · high distress / dilution risk$0.70+4%today-77% from 52w high
Lead: cachexia and other GDF-15-driven diseases
Revenue
pre-revenue
Liquidity
$7M
Runway
0.2 yrs
Shares 1y
+157%
Price & events
-23.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.8%
1D
-2.2%
1W
+6.8%
1M
-20.8%
3M
-16.3%
6M
+95.4%
1Y
-69.0%
2Y
-94.9%
5Y
-96.8%
All
Overview
- Market Cap
- $74.25M
- Volume
- 223.18K
- 52 Week Range
- $0.24 – $2.97
- Total Shares
- 106.46M
- Float Shares
- 89.12M
- Short %
- 8.99%
- % Held by Insiders
- 8.44%
- % Held by Institutions
- 14.65%
- RVOL
- 0.09x
- Beta
- 0.06
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 8
- 2026trial initiationsecondaryFL-501 · Plan to begin clinical trialSEC 8-K
- 2026-08-13earningsEarningsEarnings releaseyahoo
- 2026-05-21fda agreementRegained compliance with Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement.SEC 8-K
- Mini Oral Session at ESMO Congress 2025 on October 19conferencedata presentationsecondaryPhase 2sirexatamab · Phase 2 trial results presented at ESMO 2025SEC 8-K
- 2025-10-06partnershipPrivate placement with Winklevoss Capital for $58.88M to initiate digital asset treasury strategySEC 8-K
- 2025-10-06partnershipEntered into Securities Purchase Agreement for private placement of shares and warrants, raising ~$58.88M gross proceeds.SEC 8-K
- mid 2025readoutPhase 2DKN-01 · Initial data from Part B including left-sided CRC subpopulationSEC 8-K
- April 25-30, 2025conferencedata presentationsecondaryFL-501 · Preclinical data to be presented at AACR 2025SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $1 (+29% upside) · 1 analysts
- 2026-07-01Cantor FitzgeraldOverweight
Competitors — cachexia and other GDF-15-driven diseases
- none identified
Recent news
- 2026-07-21Cypherpunk Technologies Faces Nasdaq Listing Compliance Warning - TipRanks
- 2026-07-21Cypherpunk Technologies Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
- 2026-07-21Nasdaq warns Cypherpunk Technologies (Nasdaq: CYPH) on $1 bid rule - Stock Titan
- 2026-07-18Enterprise value to EBITDA forward of Cypherpunk Technologies Inc. – NASDAQ:CYPH - TradingView
- 2026-07-12Cypherpunk Technologies Inc Stock Historical Valuations | HAM:5MC - GuruFocus
- 2026-07-12Cypherpunk Technologies Inc Stock Warning Signs | HAM:5MC - GuruFocus
- 2026-07-12Cypherpunk Technologies Inc Stock Operating Data - GuruFocus
- 2026-07-12Cypherpunk Technologies Inc (HAM:5MC) Stock Earnings Transcripts - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.